{"filing":{"accession_number":"0001193125-26-335010","cik":"0001439725","ticker":"BDSX","company_name":"BIODESIX INC","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"bdsx-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1439725/000119312526335010/bdsx-20260805.htm"},"events":[{"id":24712,"run_id":22408,"accession_number":"0001193125-26-335010","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a straightforward earnings release for Q2 2026 ended June 30, 2026, filed on August 5, 2026. The press release (Exhibit 99.1) announces financial and operating results including revenue of $26.9 million (34% growth), gross margin of 82%, and net loss of $7.3 million, along with full-year 2026 guidance. The Item 2.02 disclosure explicitly states the company \"issued a press release announcing the financial and operating results\" and incorporates the exhibit by reference, which is the standard format for earnings releases on Form 8-K.","company_name":"BIODESIX INC","ticker":"BDSX","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25364,"accession_number":"0001193125-26-335010","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a straightforward earnings release for Q2 2026 ended June 30, 2026, filed on August 5, 2026. The press release (Exhibit 99.1) announces financial and operating results including revenue of $26.9 million (34% growth), gross margin of 82%, and net loss of $7.3 million, along with full-year 2026 guidance. The Item 2.02 disclosure explicitly states the company \"issued a press release announcing the financial and operating results\" and incorporates the exhibit by reference, which is the standard format for earnings releases on Form 8-K.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:15:20.409389+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25364,"accession_number":"0001193125-26-335010","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a straightforward earnings release for Q2 2026 ended June 30, 2026, filed on August 5, 2026. The press release (Exhibit 99.1) announces financial and operating results including revenue of $26.9 million (34% growth), gross margin of 82%, and net loss of $7.3 million, along with full-year 2026 guidance. The Item 2.02 disclosure explicitly states the company \"issued a press release announcing the financial and operating results\" and incorporates the exhibit by reference, which is the standard format for earnings releases on Form 8-K.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:15:20.409389+00:00","company_name":"BIODESIX INC","ticker":"BDSX","filing_date":"2026-08-05"}]}